One Cetc Potevio Science&Technology Co.,Ltd. (SZSE:002544) Analyst Just Cut Their EPS Forecasts
One Cetc Potevio Science&Technology Co.,Ltd. (SZSE:002544) Analyst Just Cut Their EPS Forecasts
Today is shaping up negative for Cetc Potevio Science&Technology Co.,Ltd. (SZSE:002544) shareholders, with the covering analyst delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per share (EPS) estimates were cut sharply as the analyst factored in the latest outlook for the business, concluding that they were too optimistic previously.
今天对Cetc Potevio科学与技术公司来说是负面的。,Ltd.(深圳证券交易所:002544)的股东,封面分析师对今年的预测进行了大幅的负面修正。收入和每股收益(EPS)的预期均大幅下调,原因是分析师将最新的业务前景考虑在内,得出结论,此前他们过于乐观。
Following the downgrade, the most recent consensus for Cetc Potevio Science&TechnologyLtd from its one analyst is for revenues of CN¥7.1b in 2023 which, if met, would be an okay 3.6% increase on its sales over the past 12 months. Per-share earnings are expected to step up 18% to CN¥0.27. Previously, the analyst had been modelling revenues of CN¥8.0b and earnings per share (EPS) of CN¥0.36 in 2023. Indeed, we can see that the analyst is a lot more bearish about Cetc Potevio Science&TechnologyLtd's prospects, administering a measurable cut to revenue estimates and slashing their EPS estimates to boot.
降级之后,Cetc Potevio Science&TechnologyLtd的一位分析师对2023年收入为71亿元人民币的最新共识,如果得到满足,其销售额将比过去12个月的销售额增长3.6%。每股收益预计将增长18%,至0.27元人民币。此前,该分析师一直在模拟2023年的收入为80亿元人民币,每股收益(EPS)为0.36元人民币。事实上,我们可以看出,分析师对Cetc Potevio Science&TechnologyLtd的前景更加悲观,他大幅削减了收入预期,并下调了每股收益预期。
Check out our latest analysis for Cetc Potevio Science&TechnologyLtd
查看我们对 Cetc Potevio Science&TechnologyLtd 的最新分析
The analyst made no major changes to their price target of CN¥24.33, suggesting the downgrades are not expected to have a long-term impact on Cetc Potevio Science&TechnologyLtd's valuation.
该分析师没有对24.33元人民币的目标股价做出重大调整,这表明下调评级预计不会对Cetc Potevio Science&TechnologyLtd的估值产生长期影响。
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Cetc Potevio Science&TechnologyLtd's rate of growth is expected to accelerate meaningfully, with the forecast 3.6% annualised revenue growth to the end of 2023 noticeably faster than its historical growth of 2.8% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to see revenue growth of 23% annually. It seems obvious that, while the future growth outlook is brighter than the recent past, Cetc Potevio Science&TechnologyLtd is expected to grow slower than the wider industry.
了解这些预测的更多背景信息的一种方法是研究它们与过去的业绩相比如何,以及同一行业中其他公司的表现。从最新估计中可以明显看出,Cetc Potevio Science&TechnologyLtd的增长率预计将大幅加快,预计到2023年底的年化收入增长率为3.6%,明显快于其过去五年中每年2.8%的历史增长。相比之下,同行业的其他公司预计年收入将增长23%。显而易见,尽管未来的增长前景比最近更光明,但预计Cetc Potevio Science&TechnologyLtd的增长速度将低于整个行业。
The Bottom Line
底线
The biggest issue in the new estimates is that the analyst has reduced their earnings per share estimates, suggesting business headwinds lay ahead for Cetc Potevio Science&TechnologyLtd. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on Cetc Potevio Science&TechnologyLtd after the downgrade.
新估计中最大的问题是,分析师下调了每股收益预期,这表明Cetc Potevio Science&TechnologyLtd面临业务不利因素。遗憾的是,他们还下调了收入预期,最新的预测表明该业务的销售增长将慢于整个市场。我们还惊讶地看到目标股价保持不变。尽管如此,业务状况仍在恶化(假设预测准确!)可以成为股价的主要指标,因此我们不会责怪投资者在降级后对Cetc Potevio Science&TechnologyLtd更加谨慎。
Uncomfortably, our automated valuation tool also suggests that Cetc Potevio Science&TechnologyLtd stock could be overvalued following the downgrade. Shareholders could be left disappointed if these estimates play out. Find out why, and see how we estimate the valuation for free on our platform here.
令人不安的是,我们的自动估值工具还表明,降级后Cetc Potevio Science&TechnologyLtd的股票可能会被高估。如果这些估计得以实现,股东们可能会感到失望。在此处了解原因,并查看我们如何在平台上免费估算估值。
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
当然,看到公司管理层将大量资金投资于股票与了解分析师是否在下调预期一样有用。因此,您可能还希望搜索这份内部人士正在购买的免费股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。